Prior antimicrobial therapy and risk for hospital-acquired Candida glabrata and Candida krusei fungemia: a case-case-control study. - Test2 - elhamkhani - TriplyDB

Prior antimicrobial therapy and risk for hospital-acquired Candida glabrata and Candida krusei fungemia: a case-case-control study.

Prior antimicrobial therapy and risk for hospital-acquired Candida glabrata and Candida krusei fungemia: a case-case-control study.

http://www.wikidata.org/entity/Q34123634

about

Candida krusei, a multidrug-resistant opportunistic fungal pathogen: geographic and temporal trends from the ARTEMIS DISK Antifungal Surveillance Program, 2001 to 2005 Genome engineering in the yeast pathogen Candida glabrata using the CRISPR-Cas9 system Epidemiology, species distribution, antifungal susceptibility and outcome of nosocomial candidemia in a tertiary care hospital in Italy Epidemiology of invasive candidiasis: a persistent public health problem Hospital epidemiology and infection control in acute-care settings.A cluster of Candida krusei infections in a haematological unit.Epidemiology of Candida albicans and non-C.albicans of neonatal candidemia at a tertiary care hospital in western China The effect of cumulative length of hospital stay on the antifungal resistance of Candida strains isolated from critically ill surgical patients.Risk factors for fluconazole-resistant Candida glabrata bloodstream infections Nationwide sentinel surveillance of bloodstream Candida infections in 40 tertiary care hospitals in Spain Recent exposure to caspofungin or fluconazole influences the epidemiology of candidemia: a prospective multicenter study involving 2,441 patients Epidemiology of candidemia in Brazil: a nationwide sentinel surveillance of candidemia in eleven medical centers Antibiotic exposure as a risk factor for fluconazole-resistant Candida bloodstream infection Impact of prior inappropriate fluconazole dosing on isolation of fluconazole-nonsusceptible Candida species in hospitalized patients with candidemia.Invasive candidiasis in Pakistan: clinical characteristics, species distribution and antifungal susceptibility.Nosocomial fungal infections: epidemiology, diagnosis, and treatment.Epidemiology of invasive fungal infections in the intensive care unit: results of a multicenter Italian survey (AURORA Project)Antimicrobial resistance: resistance to antifungal agents: mechanisms and clinical impact.Current options in antifungal pharmacotherapy.Treatment of invasive candidiasis in the elderly: a review A single-centre 10-year experience with Candida bloodstream infections.Blood stream infections by Candida glabrata and Candida krusei: a single-center experience Epidemiology, species distribution, antifungal susceptibility, and outcome of candidemia across five sites in Italy and Spain.Azole Antifungal Resistance in Candida albicans and Emerging Non-albicans Candida Species.Invasive fungal infections in the ICU.Diagnosis and treatment of fungal infections in allogeneic stem cell and solid organ transplant recipients.Antifungal susceptibility testing: a primer for clinicians.Fungal infections in burns: a comprehensive review.Concise review: next-generation cell therapies to prevent infections in neutropenic patients.Differences in epidemiology of candidaemia in the Nordic countries - what is to blame?Risk factors for fluconazole-resistant candidemia.Cross-resistance between voriconazole and fluconazole for non-albicans Candida infection: a case-case-control study.Factors Influencing Non-albicans Candidemia: A Case-Case-Control Study.Epidemiology of candidaemia in a tertiary care university hospital: 10-year experience with 381 candidaemia episodes between 2001 and 2010.Epidemiology and outcome of nosocomial candidemia in elderly patients admitted prevalently in medical wards.Prior antimicrobial exposure and the risk for bloodstream infection with fluconazole-non-susceptible Candida strains.Fungaemia caused by Candida glabrata with reduced susceptibility to fluconazole due to altered gene expression: risk factors, antifungal treatment and outcome.Factors associated with candidemia caused by non-albicans Candida species versus Candida albicans in the intensive care unit.Seven-year trend analysis of nosocomial candidemia and antifungal (fluconazole and caspofungin) use in Intensive Care Units at a Brazilian University Hospital.Fluconazole-resistant Candida: collateral damage associated with prior antibacterial exposure?

P2860

Q28260910-F35205C1-D811-411E-8BB8-7FB50EE887AA Q28597069-01B9FAF9-A09E-400A-A4E9-B8C93A9FAE94 Q28740362-612A145B-C579-4C25-A00B-57719D6E6C36 Q29616758-BAA8DC0C-50C1-4D75-A087-A99A0C0EAB89 Q30429049-98C42453-EC2C-4A2B-8EBD-3D0A0E3D2F8A Q33294780-3BDE0186-C534-49B3-96A6-102D2FC98F67 Q33644932-181D2349-F00B-4533-AEDA-D4C1E5C1FA1E Q33887429-082A408C-4194-48CE-B276-349F4DA120DA Q33932340-47219E3D-75AF-4AA8-A5BE-0494FDB97776 Q34489579-B16A5AF6-48A9-4B98-AB44-3F2AB1EFB3BA Q34529026-D2D1B99B-FC37-4EA2-BCFE-74FB1AB43C84 Q35073043-F33CC991-5320-4771-AAF6-DBDDEDDD2947 Q35941512-63E5B2A8-F8A0-4F60-B8A3-C26440341B8B Q36018860-A887FD34-0A58-48FA-94D7-3D256A0AF5F5 Q36237993-78D175D2-1340-4ADA-8A6D-915F8600B813 Q36825717-BC66EA49-A13D-4064-AF43-83D81509B169 Q36898053-F168B8AF-9A34-44BC-BA5E-98A923904012 Q37048679-67A38B75-2EA3-41C5-AD47-7FC7773E3F04 Q37151326-87CF774C-9142-418A-BE84-C61179B22F2F Q37170218-65FDEC2A-DC0A-4458-A170-FFAC8A2777A1 Q37252122-2635123F-C697-494E-AB6D-BD9B3DD803E3 Q37320979-C445F753-2A67-4EE9-8BDD-539B81046004 Q37336194-72DDF8EC-C487-49F3-841D-C57B9D8B5BEE Q37580801-F7FCF794-0AF1-416C-B1B0-79F402F3D193 Q37643057-B00EE220-57FF-414F-B09E-8DAE2155723A Q37650317-9D4F6C2B-7695-4647-888C-75ECE83A86F1 Q38061087-C0283F66-9636-472F-9538-8547A200D7BA Q38190539-2AB9D799-63CA-4EA5-B57E-3DF754212409 Q38193653-324A1508-E4E8-40E1-9862-B192FEEAA1EB Q39553745-72D81665-BCF1-4D8B-85E1-872E7F87AB05 Q39934814-B5D14AE2-49B0-4BE8-A20A-1B6EEA877EAC Q40169961-9A29B1AE-B9BC-4EE2-BB94-B34D4FD0A0CD Q40205203-09DAD156-82DE-4404-AB1C-CDD066F0FFF8 Q40757551-610243DD-429E-45C7-8BFE-603C977CB746 Q42210762-FB75EA42-CA64-4F78-9EF1-68174F2FE969 Q43108559-5F5EBAA1-02D7-450D-8097-250056CBDE7F Q43701370-154DA600-6189-4058-B463-710CC82DB000 Q43737173-43CC273C-4B74-4392-A7B1-F026D62F0D34 Q44693688-F4607113-D4B5-4083-8166-A246569862D9 Q44919501-EC0A78ED-D9A0-4530-B6EE-A1475A9D0E37

P2860

Prior antimicrobial therapy and risk for hospital-acquired Candida glabrata and Candida krusei fungemia: a case-case-control study.

http://www.wikidata.org/entity/Q34123634

description

2005 nî lūn-bûn

@nan

2005 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2005 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

name

Prior antimicrobial therapy an ...... ia: a case-case-control study.

@ast

Prior antimicrobial therapy an ...... ia: a case-case-control study.

@en

Prior antimicrobial therapy an ...... ia: a case-case-control study.

@nl

type

label

Prior antimicrobial therapy an ...... ia: a case-case-control study.

@ast

Prior antimicrobial therapy an ...... ia: a case-case-control study.

@en

Prior antimicrobial therapy an ...... ia: a case-case-control study.

@nl

prefLabel

Prior antimicrobial therapy an ...... ia: a case-case-control study.

@ast

Prior antimicrobial therapy an ...... ia: a case-case-control study.

@en

Prior antimicrobial therapy an ...... ia: a case-case-control study.

@nl

P1433

Q34123634-F6B6A44A-105E-4BB4-9792-9715A273AA57

P1476

Q34123634-637FE4AB-BB2E-499F-A810-B8926EC7ADAB

P2093

Q34123634-4A6A1F05-B9FE-4B20-A978-864B86CCD512

Q34123634-57DFF285-E610-4065-9EBC-FC40832BB904

Q34123634-B97AE619-4D54-408E-9F7C-89D4819A5FE6

Q34123634-C33FF902-A902-4A7A-9598-840A3FC81F52

Q34123634-DF8B2232-E2AF-4460-A86D-9D66F81860A2

Q34123634-EA7F0B8A-ED64-43F9-8FBB-A4E261579829

Q34123634-F46D6191-64E4-423D-9A46-994115B57146

P2860

Q34123634-13CC3B81-A264-4163-B50C-0FA0487C8CDD

Q34123634-14CCCAB0-F951-4AD3-9A85-EB70D972B38C

Q34123634-235862BA-6E71-44D1-9728-D17E7E84D564

Q34123634-3FC61C3E-A68E-46CC-A693-4082123A011E

Q34123634-49D1F488-A509-4BB1-9D7E-3CA28E46160D

Q34123634-59A8D561-5AEA-4B5E-9DC9-A55E94CE0683

Q34123634-5F4D1B10-5A0A-4CA5-B2F6-AA37D36C444D

Q34123634-644BC428-2130-40F4-9D6E-97FFEC27C827

Q34123634-66575A58-77DA-49D5-856C-DF57504C1B30

Q34123634-72A2F18B-6ACA-4328-B44D-E128F54E1E57

P304

Q34123634-79C5AE35-58A6-4DBB-BD58-52E119E7850C

P31

Q34123634-0755698B-66CF-456A-A5DC-E40AAEF2CC2D

P356

Q34123634-41A390F1-EEAC-4001-81DC-AEDA8938011C

P407

Q34123634-F05A1CF3-7D8C-484B-AB15-310BEF963432

P433

Q34123634-6CEC22B6-4157-4A99-A064-C27AB7033471

P478

Q34123634-63EF8CE9-AB91-4086-BD54-E9E8971170BB

P577

Q34123634-BA5F2C90-28DD-45E7-818F-53C4F8FE5BAE

P5875

Q34123634-3B3E8C14-3F1E-4D39-A9E8-1885F154D744

P698

Q34123634-1B8C2A2B-DF44-4ECB-91F6-6D0A7F75D7EE

P921

Q34123634-4F0533F1-E0B2-400C-9D8C-8553CDDA8A83

P932

Q34123634-9D473099-73F7-4C5B-BD95-0C9615573D4D

P356

AAC.49.11.4555-4560.2005

P1433

Antimicrobial Agents and Chemotherapy

P1476

Prior antimicrobial therapy an ...... ia: a case-case-control study.

@en

P2093

Ernesto L Flores

http://www.w3.org/2001/XMLSchema#string

Jennifer Zumsteg

http://www.w3.org/2001/XMLSchema#string

Jocelyn Tolentino

http://www.w3.org/2001/XMLSchema#string

Michael Y Lin

http://www.w3.org/2001/XMLSchema#string

Pranavi Sreeramoju

http://www.w3.org/2001/XMLSchema#string

Stephen G Weber

http://www.w3.org/2001/XMLSchema#string

Yehuda Carmeli

http://www.w3.org/2001/XMLSchema#string

P2860

The role of 'confounding by indication' in assessing the effect of quality of care on disease outcomes in general practice: results of a case-control study

Prophylactic fluconazole in liver transplant recipients. A randomized, double-blind, placebo-controlled trial

Trends in antifungal susceptibility of Candida spp. isolated from pediatric and adult patients with bloodstream infections: SENTRY Antimicrobial Surveillance Program, 1997 to 2000.

Emerging evidence of selection of fluconazole-tolerant fungi in surgical intensive care units.

Nosocomial Candida glabrata colonization: an epidemiologic study.

Risk factors for recovery of ampicillin-sulbactam-resistant Escherichia coli in hospitalized patients.

Clinical isolation and resistance patterns of and superinfection with 10 nosocomial pathogens after treatment with ceftriaxone versus ampicillin-sulbactam

In vitro activities of ravuconazole and voriconazole compared with those of four approved systemic antifungal agents against 6,970 clinical isolates of Candida spp.

Fluoroquinolones and the risk for methicillin-resistant Staphylococcus aureus in hospitalized patients.

Non-albicans Candida spp. causing fungaemia: pathogenicity and antifungal resistance.

P304

4555-4560

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/AAC.49.11.4555-4560.2005

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

49

http://www.w3.org/2001/XMLSchema#string

P577

2005-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7515951

http://www.w3.org/2001/XMLSchema#string

P698

16251295

http://www.w3.org/2001/XMLSchema#string

P921

Candida glabrata

P932

1280123

http://www.w3.org/2001/XMLSchema#string